Abstract
BackgroundRecently, catheter-based renal sympathetic denervation (RSD) has been verified to be safely used to substantially reduce the levels of blood pressure, left ventricular hypertrophy, sleep apnea severity and norepinephrine spillover, and improve glucose tolerance. All these pathological changes are recognized as independent risk factors for the development and recurrence of atrial fibrillation (AF). A randomized, single-blind, parallel-control, multicenter clinical trial is being conducted to compare RSD with antiarrhythmic drugs (AAD) in patients with drug-resistant hypertension and symptomatic AF (RSDforAF trial).Methods/designPatients with drug-resistant hypertension and symptomatic AF will be randomized to RSD and the drug treatment groups. Patients will be followed for 12 months until study closure. Up to 200 patients may be enrolled in six medical centers in China. The primary objective is to study the effects of RSD on AF burden and blood pressure in patients with hypertension and symptomatic AF.DiscussionRSDforAF trial will test the hypothesis that RSD is superior to AAD in reducing AF burden and blood pressure in patients with drug-resistant hypertension and symptomatic AF.Trial registrationClinicalTrials.gov, NCT01713270
Highlights
Catheter-based renal sympathetic denervation (RSD) has been verified to be safely used to substantially reduce the levels of blood pressure, left ventricular hypertrophy, sleep apnea severity and norepinephrine spillover, and improve glucose tolerance
RSDforAF trial will test the hypothesis that RSD is superior to antiarrhythmic drugs (AAD) in reducing atrial fibrillation (AF) burden and blood pressure in patients with drug-resistant hypertension and symptomatic AF
We designed this randomized, parallelcontrol, multicenter clinical study to demonstrate whether RSD is superior to antiarrhythmic drugs (AAD) in reducing AF burden and blood pressure in patients with drugresistant hypertension and symptomatic AF
Summary
Cardiac catheter ablation for AF has become a very commonly and widely accepted procedure in recent years, but the low success rate and high recurrence after procedure in the short and long term is disappointing. In 2012, using animal models, Zhao and colleagues [24] reported that episodes of AF could be decreased by renal sympathetic denervation during short-term rapid atrial pacing. This effect might have a relationship with the decreased activity of the reninangiotensin-aldosterone system. In 2009, the Australian researchers Krum and colleagues [3] reported for the first time that percutaneous renal sympathetic denervation acquired positive and sustained blood pressure reduction in patients with resistant hypertension. In addition to the known effect on blood pressure, the study by Brandt and colleagues [5] showed renal denervation significantly reduces left ventricular mass and improves diastolic function. Author details 1Cardiovascular Department, The First Affiliated Hospital of Nanjing Medical University, No 300, Guangzhou Road, Nanjing, Jiangsu 210029, China. 2Cardiovascular Department, The Second Affiliated Hospital of Chongqing Medical University, No 76, Linjiang Road, Chongqing, China
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
